Chief Medical Officer · Replimune Group, Inc. (REPL)

Andrea Pirzkall

FY2021 is the first fiscal year CompBrief holds for Andrea Pirzkall as a named executive officer of Replimune; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$4,726,571

Salary $261,399Stock awards $0

1st of 3 named executive officers at Replimune by FY2021 total.

3 named officers on file for Replimune, FY2021

Andrea Pirzkall’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Replimune’s whole pay program stands against its peers

  • Replimune’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on REPL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 22, 2021 (DEF 14A).

Free

Get Andrea Pirzkall’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Andrea Pirzkall compensation by year

Replimune Summary Compensation Table · the one fiscal year held
In US dollars, as Replimune reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$261,399
Bonus$0
Stock awards$0
Option awards$4,379,910
Non-equity incentive$85,262
Pension and deferred compensation$0
All other$0
Total$4,726,571

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Replimune Group, Inc. DEF 14A filed July 22, 2021, accession 0001104659-21-094885, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Replimune Group, Inc. filed document, accession 0001104659-21-094885. Every figure is read from that document and cited to the page and table it appears in. Filed July 22, 2021.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option300,000—$22.45

Per the Outstanding Equity Awards at Fiscal Year-End table in Replimune Group, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Replimune’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Andrea Pirzkall · this pageChief Medical Officer$4,726,571
Robert CoffinPresident and Chief Research & Development Officer$2,457,592
Philip Astley-SparkeChief Executive Officer$2,457,592

The full Replimune compensation record

free company brief

This page is one person within Replimune's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Replimune's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Andrea Pirzkall's compensation dossier · One-time report. No refunds.